Imaging recurrent prostate cancer

Tamar Sella, Darko Pucar

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Citations (Scopus)

Abstract

Introduction In the setting of recurrent prostate cancer (PCa), awareness and understanding of clinical findings are essential for accurate imaging interpretation. Accordingly, this text will first address the principles of recurrent PCa management. Subsequently, the principles of recurrent PCa evaluation with computed tomography (CT), magnetic resonance imaging (MRI), transrectal ultrasound (TRUS), and TRUS-guided biopsy will be described. Nuclear medicine methods are reviewed in Chapter 11. Management principles of recurrent prostate cancer General principles Prostate cancer is usually suspected based on the detection of an abnormal serum prostate-specific antigen (PSA) value (≥4 ng/ml is the most commonly used criterion) and diagnosed by TRUS-guided systematic prostate biopsy [1]. With systematic biopsy, one or more cores are obtained from each prostate sextant regardless of TRUS findings [2]. Although optional additional cores can be obtained from regions that are abnormal on TRUS or other imaging modalities, image-guided biopsy is currently accepted only as an adjunct to systematic biopsy [2]. Biopsy results are used to assign the Gleason grade [3]. Digital rectal examination (DRE) findings are used to determine clinical tumor stage; however, due to earlier detection by PSA testing, PCa is now non-palpable in about two-thirds of patients and the clinical stage often underestimates the pathologic tumor stage [4, 5] (Table 12.1). Newly diagnosed PCa is designated as “primary” PCa and its treatment modalities are designated as “primary” treatments.

Original languageEnglish (US)
Title of host publicationProstate Cancer
PublisherCambridge University Press
Pages195-222
Number of pages28
ISBN (Electronic)9780511551994
ISBN (Print)9780521887045
DOIs
StatePublished - Jan 1 2008

Fingerprint

Prostatic Neoplasms
Biopsy
Prostate-Specific Antigen
Prostate
Image-Guided Biopsy
Digital Rectal Examination
Nuclear Medicine
Neoplasms
Tomography
Magnetic Resonance Imaging
Therapeutics
Serum

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Sella, T., & Pucar, D. (2008). Imaging recurrent prostate cancer. In Prostate Cancer (pp. 195-222). Cambridge University Press. https://doi.org/10.1017/CBO9780511551994.014

Imaging recurrent prostate cancer. / Sella, Tamar; Pucar, Darko.

Prostate Cancer. Cambridge University Press, 2008. p. 195-222.

Research output: Chapter in Book/Report/Conference proceedingChapter

Sella, T & Pucar, D 2008, Imaging recurrent prostate cancer. in Prostate Cancer. Cambridge University Press, pp. 195-222. https://doi.org/10.1017/CBO9780511551994.014
Sella T, Pucar D. Imaging recurrent prostate cancer. In Prostate Cancer. Cambridge University Press. 2008. p. 195-222 https://doi.org/10.1017/CBO9780511551994.014
Sella, Tamar ; Pucar, Darko. / Imaging recurrent prostate cancer. Prostate Cancer. Cambridge University Press, 2008. pp. 195-222
@inbook{0a66cbfb00bd4e25ae19d0078a45b9b1,
title = "Imaging recurrent prostate cancer",
abstract = "Introduction In the setting of recurrent prostate cancer (PCa), awareness and understanding of clinical findings are essential for accurate imaging interpretation. Accordingly, this text will first address the principles of recurrent PCa management. Subsequently, the principles of recurrent PCa evaluation with computed tomography (CT), magnetic resonance imaging (MRI), transrectal ultrasound (TRUS), and TRUS-guided biopsy will be described. Nuclear medicine methods are reviewed in Chapter 11. Management principles of recurrent prostate cancer General principles Prostate cancer is usually suspected based on the detection of an abnormal serum prostate-specific antigen (PSA) value (≥4 ng/ml is the most commonly used criterion) and diagnosed by TRUS-guided systematic prostate biopsy [1]. With systematic biopsy, one or more cores are obtained from each prostate sextant regardless of TRUS findings [2]. Although optional additional cores can be obtained from regions that are abnormal on TRUS or other imaging modalities, image-guided biopsy is currently accepted only as an adjunct to systematic biopsy [2]. Biopsy results are used to assign the Gleason grade [3]. Digital rectal examination (DRE) findings are used to determine clinical tumor stage; however, due to earlier detection by PSA testing, PCa is now non-palpable in about two-thirds of patients and the clinical stage often underestimates the pathologic tumor stage [4, 5] (Table 12.1). Newly diagnosed PCa is designated as “primary” PCa and its treatment modalities are designated as “primary” treatments.",
author = "Tamar Sella and Darko Pucar",
year = "2008",
month = "1",
day = "1",
doi = "10.1017/CBO9780511551994.014",
language = "English (US)",
isbn = "9780521887045",
pages = "195--222",
booktitle = "Prostate Cancer",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - Imaging recurrent prostate cancer

AU - Sella, Tamar

AU - Pucar, Darko

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Introduction In the setting of recurrent prostate cancer (PCa), awareness and understanding of clinical findings are essential for accurate imaging interpretation. Accordingly, this text will first address the principles of recurrent PCa management. Subsequently, the principles of recurrent PCa evaluation with computed tomography (CT), magnetic resonance imaging (MRI), transrectal ultrasound (TRUS), and TRUS-guided biopsy will be described. Nuclear medicine methods are reviewed in Chapter 11. Management principles of recurrent prostate cancer General principles Prostate cancer is usually suspected based on the detection of an abnormal serum prostate-specific antigen (PSA) value (≥4 ng/ml is the most commonly used criterion) and diagnosed by TRUS-guided systematic prostate biopsy [1]. With systematic biopsy, one or more cores are obtained from each prostate sextant regardless of TRUS findings [2]. Although optional additional cores can be obtained from regions that are abnormal on TRUS or other imaging modalities, image-guided biopsy is currently accepted only as an adjunct to systematic biopsy [2]. Biopsy results are used to assign the Gleason grade [3]. Digital rectal examination (DRE) findings are used to determine clinical tumor stage; however, due to earlier detection by PSA testing, PCa is now non-palpable in about two-thirds of patients and the clinical stage often underestimates the pathologic tumor stage [4, 5] (Table 12.1). Newly diagnosed PCa is designated as “primary” PCa and its treatment modalities are designated as “primary” treatments.

AB - Introduction In the setting of recurrent prostate cancer (PCa), awareness and understanding of clinical findings are essential for accurate imaging interpretation. Accordingly, this text will first address the principles of recurrent PCa management. Subsequently, the principles of recurrent PCa evaluation with computed tomography (CT), magnetic resonance imaging (MRI), transrectal ultrasound (TRUS), and TRUS-guided biopsy will be described. Nuclear medicine methods are reviewed in Chapter 11. Management principles of recurrent prostate cancer General principles Prostate cancer is usually suspected based on the detection of an abnormal serum prostate-specific antigen (PSA) value (≥4 ng/ml is the most commonly used criterion) and diagnosed by TRUS-guided systematic prostate biopsy [1]. With systematic biopsy, one or more cores are obtained from each prostate sextant regardless of TRUS findings [2]. Although optional additional cores can be obtained from regions that are abnormal on TRUS or other imaging modalities, image-guided biopsy is currently accepted only as an adjunct to systematic biopsy [2]. Biopsy results are used to assign the Gleason grade [3]. Digital rectal examination (DRE) findings are used to determine clinical tumor stage; however, due to earlier detection by PSA testing, PCa is now non-palpable in about two-thirds of patients and the clinical stage often underestimates the pathologic tumor stage [4, 5] (Table 12.1). Newly diagnosed PCa is designated as “primary” PCa and its treatment modalities are designated as “primary” treatments.

UR - http://www.scopus.com/inward/record.url?scp=77953428557&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953428557&partnerID=8YFLogxK

U2 - 10.1017/CBO9780511551994.014

DO - 10.1017/CBO9780511551994.014

M3 - Chapter

AN - SCOPUS:77953428557

SN - 9780521887045

SP - 195

EP - 222

BT - Prostate Cancer

PB - Cambridge University Press

ER -